Pre-made Pertuzumab biosimilar ( Whole mAb, anti-ERBB2 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-439
Anti-ERBB2 therapeutic antibody (Pre-made Pertuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-ERBB2 therapeutic antibody (Pre-made Pertuzumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||1l7i:HL/4llu:AB:CD/1s78:FE:DC|
|99% SI Structure||None|
|95-98% SI Structure||4lly:AB:CD/4llw:CD:AB/5vsh:CD:AB:EF:HL|
|Companies||Chugai Pharmaceutical;Dana-Farber Cancer Institute;FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO;Genentech;International Breast Cancer Study Group;Japan Breast Cancer Research Group;Medica Scientia Innovation Research;Roche;West German Study Group|
|Conditions Approved||Breast cancer|
|Conditions Active||Ovarian cancer;Brain metastases;Colorectal cancer|
|Conditions Discontinued||Gastric cancer;Non-small cell lung cancer;Prostate cancer|